The UK’s newly-aggressive Financial Services Authority (FSA) is pursuing another high-profile insider trading case, as reports emerged today that a partner at the London office of Dorsey & Whitney and a former partner of McDermott Will & Emery will be charged criminally next month with insider trading. Bloomberg reports that Andrew Rimmington, a corporate partner at Dorsey & Whitney LLP, and Michael Gerard McFall, an ex-corporate partner at McDermott Will & Emery LLP, are the lawyers in question, along with Peter Andrew William King, the former financial director of Neutec Pharma Ltd. The prosecution relates to Novartis AG’s 2006 takeover of Neutec, according to court documents.
According to Bloomberg, King and McFall face charges of insider dealing and disclosing non-public information, while Rimmington will only be charged with insider trading.
